Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Wages, Salaries and Other
Others
Ratios

Revolution Medicines (RVMD) Research & Development (2019 - 2025)

Revolution Medicines (RVMD) has 7 years of Research & Development data on record, last reported at $294.9 million in Q4 2025.

  • For Q4 2025, Research & Development rose 56.8% year-over-year to $294.9 million; the TTM value through Dec 2025 reached $987.3 million, up 66.72%, while the annual FY2025 figure was $987.3 million, 66.72% up from the prior year.
  • Research & Development reached $294.9 million in Q4 2025 per RVMD's latest filing, up from $262.5 million in the prior quarter.
  • Across five years, Research & Development topped out at $294.9 million in Q4 2025 and bottomed at $40.9 million in Q1 2021.
  • Average Research & Development over 5 years is $122.1 million, with a median of $102.9 million recorded in 2023.
  • The widest YoY moves for Research & Development: up 124.54% in 2023, down 22.05% in 2023.
  • A 5-year view of Research & Development shows it stood at $53.7 million in 2021, then rose by 23.19% to $66.1 million in 2022, then skyrocketed by 124.54% to $148.5 million in 2023, then increased by 26.68% to $188.1 million in 2024, then soared by 56.8% to $294.9 million in 2025.
  • Per Business Quant database, its latest 3 readings for Research & Development were $294.9 million in Q4 2025, $262.5 million in Q3 2025, and $224.1 million in Q2 2025.